Format

Send to

Choose Destination
Clin Cancer Res. 2008 Apr 15;14(8):2249-52. doi: 10.1158/1078-0432.CCR-07-1005.

Targeting Ras in myeloid leukemias.

Author information

1
Department of Pediatrics, University of California, San Francisco, CA 94143, USA. braunb@peds.ucsf.edu <braunb@peds.ucsf.edu>

Abstract

Ras proteins normally relay growth-promoting signals from many activated cell surface receptors, and they are altered by oncogenic point mutations in approximately 30% of human cancers. Activating KRAS and NRAS mutations are especially common in malignancies of the pancreas, lung, and colon, and in myeloid leukemia. Here, we discuss general strategies for targeting hyperactive Ras signaling in cancer cells with specific reference to myeloid malignancies.

PMID:
18413813
DOI:
10.1158/1078-0432.CCR-07-1005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center